Citius Oncology (CTOR) Fundamental Analysis: Revenue, Earnings & Valuation

0.52 / 10

Underperform

Fundamental rating is Underperform with a 0.5/10 score. Asset and revenue metrics are marginal, profit and cash positions are weak, and profit margins are deeply negative, indicating severely challenged financial health.

Analysis Checks(4/10)

Revenue-MV

Value-0.11

Score3/3

Weight-18.80%

1M Return3.85%

Net cash flow from operating activities / Operating revenue (%)

Value-982.50

Score0/3

Weight31.87%

1M Return-9.58%

Profit-MV

Value0.66

Score1/3

Weight11.31%

1M Return-2.85%

Net income-Revenue

Value-0.04

Score1/3

Weight10.12%

1M Return-2.58%

Net profit margin (%)

Value-1264.47

Score0/3

Weight31.19%

1M Return-9.31%

Cash-UP

Value-0.15

Score3/3

Weight-11.88%

1M Return2.45%

Net cash flow from operating activities / Total liabilities (%)

Value-0.10

Score3/3

Weight-11.48%

1M Return2.78%

EBIT / Total operating revenue (%)

Value-1049.47

Score0/3

Weight30.53%

1M Return-9.03%

Asset-MV

Value-0.55

Score2/3

Weight-4.05%

1M Return0.95%

Net profit / Total operating revenue (%)

Value-654.10

Score0/3

Weight31.19%

1M Return-9.31%

Is CTOR undervalued or overvalued?

CTOR scores 0.52/10 on fundamentals and holds a Premium valuation at present. Backed by its -10.72% ROE, 0.00% net margin, -2.42 P/E ratio, 0.98 P/B ratio, and 6.06% earnings growth, these metrics solidify its Underperform investment rating.